Software-reconfigurable system delivers eight distinct configurations across a multi-vendor stack, now in active use by partners.

OXFORDSHIRE, United Kingdom, April 23, 2026 — TreQ has designed, built, and brought online its Open-Architecture Quantum (OAQ) Testbed, a fully operational, multi-vendor system now in active use. Part of Innovate UK’s Quantum Mission Pilot, the system operates independent processor, control, and software layers through well-defined interfaces. This enables:

• Reconfiguration and upgrades without rebuilding the stack
• Efficient system-level evaluation and comparison of potential builds
• Portability of solutions across configurations

“Open architecture quantum requires systems engineering to define interfaces, validate integration, and operate at system scale. It is much more than assembling components from multiple vendors,” said Mandy Birch, Founder and CEO of TreQ. “With the OAQ Testbed in operation, we’ve demonstrated that capital-efficient, flexible quantum infrastructure can be built and operated today.”

In just 3 months, from procurement to deployment within its purpose-built facility, TreQ brought online a complete multi-dimensional system that integrates products from across the industry. The team coordinated long-lead components from multiple suppliers and validated performance across multiple configurations.

Beginning with two options each for QPU, control hardware, and calibration software, the system supports eight computing configurations within the same three-rack footprint. The full system configuration can be switched via software, allowing performance assessment in different contexts without cycling or recabling the hardware.

This approach shifts quantum infrastructure from fixed configurations to adaptable architectures that incorporate best-in-class technologies. By defining core layers and integrating them through transparent interfaces, TreQ enables innovation throughout the stack and allows infrastructure investment to advance alongside a dynamic supply chain. Customers can evaluate, upgrade, and incorporate new technologies as they emerge, extending infrastructure lifetime, improving return on investment, and accelerating technical progress.

Open Architecture Quantum Validated

A world-first for open architecture, TreQ has delivered a full-stack system that enables direct evaluation and comparison within a single engineered environment. This demonstrates the viability of open-architecture approaches that rely on rigorous systems engineering rather than fixed integrations.

“The Novera QPU is designed for modularity, enabling ease of testing and integrating with new configurations and architectures. Validating the performance of the Novera QPU in different configurations within a multi-vendor architecture provides insight into system-level design and integration requirements for open architecture systems,” said Dr. Subodh Kulkarni, Rigetti CEO.

Interoperable at the Core

The OAQ Testbed’s engineered interfaces give innovators the freedom to build a stack from independently developed subsystems with low-friction, reliable interchangeability. A system orchestrator manages user requests across multiple levels of job abstraction and executes them on a selection of targets. Integrated calibration services continuously monitor and maintain system performance.

“Interoperability and autonomy are key to deployability. Running our autonomous calibration workflows on multiple configurations within a shared architecture makes it easier for users to pick the best system for their application, and achieve the best possible performance,” said Alex Shih, VP of Product at Q-CTRL.

Enabling Solution Portability

To ensure our clients’ solutions and intellectual property are portable between hardware systems, a TreQ-led consortium developed an open-source interface specification for vendor-interchangeable low-level integration. This specification has already been integrated into commercial offerings from Q-CTRL and Qruise, and demonstrated on Quantum Machines and Qblox control platforms. In collaboration with Oxford Ionics, an IonQ company, TreQ developed this specification to support multiple modalities, incorporating core operations for ion trap systems alongside superconducting processors from Rigetti and QuantWare housed in the same Maybell cryostat.

“The specification enables our AI-powered calibration technology to be deployed across more backends and increases the market reach of our solutions,” said Anurag Saha Roy, Chief Product Officer at Qruise.

Bringing Open Architecture to Market

TreQ now has a platform to efficiently expand its system offerings. This capability facilitates the evaluation of products from throughout the industry, while accelerating the incorporation of emerging offerings from a rapidly advancing supply chain.

Media Contact:
Megan Chalidis
+1 202.370.7473
[email protected]

SOURCE TreQ

• Novel bispecific antibody with a dual mechanism of action targeting anemia of inflammation in chronic kidney disease, autoimmune disease, and cancer
• Experienced leadership and advisory team with deep expertise in antibody engineering, red blood cell biology, and nephrology
• Seed financing led by Forty51 Ventures

BASEL, Switzerland, April 23, 2026 — Ferrosa Therapeutics AG (“FERROSA”), a Swiss biotechnology company developing a first-in-class bispecific antibody to treat anemia of inflammation, announced today a seed financing of USD 3.5 Million by founding investor Forty51 Ventures.

FERROSA’s lead program is a bispecific antibody designed to address key biological drivers of anemia of inflammation: cytokine-driven dysregulation of iron homeostasis that impairs erythropoiesis. The company’s proprietary dual-mechanism approach combines two complementary clinically validated pathways to restore effective red blood cell production and normalize iron availability.

Anemia of inflammation is a prevalent comorbidity in patients with chronic kidney disease, autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease, and many cancers. Existing treatments – including erythropoiesis-stimulating agents, intravenous iron, and blood transfusions – address symptoms rather than the underlying biology and carry safety risks. There is a substantial unmet medical need for therapies that mechanistically correct iron restriction and restore effective erythropoiesis.

With the current financing, FERROSA will advance its preclinical program through antibody generation, bispecific engineering, and in vivo proof-of-concept studies in disease-relevant animal models.

The company appointed co-founder Martin Stern, MD as the Chief Executive Officer. Martin Stern is a physician-scientist and board-certified hematologist with more than 25 years of combined academic and industry experience. He previously served as Chief Medical Officer at Numab Therapeutics, where he led clinical development of multispecific antibodies in oncology and immunology, and as CMO at Affivant Sciences. Earlier in his career, he held senior positions at Roche Pharma Research and Early Development (pRED). Prior to that he was clinically active as a hematologist for more than a decade.

Martin Stern commented: “Anemia of inflammation remains one of the most prevalent yet inadequately treated complications across chronic diseases. Our bispecific approach has the potential to change how clinicians manage this condition – moving beyond symptomatic support toward correction of the underlying pathophysiology. I am excited to build FERROSA and bring this differentiated therapy to patients who need it.”

FERROSA collaborates with leading experts in antibody engineering, red blood cell biology and nephrology. Dr. Beatriz Goyenechea, a recognized authority in antibody development and founder of StarBio International, serves as antibody development advisor. Prof. Stefano Rivella of the Children’s Hospital of Philadelphia advises on preclinical disease models. Prof. Beatrice Goilav, Professor of Pediatrics at the Albert Einstein College of Medicine and Montefiore Hospital, and a leading clinical researcher in chronic kidney disease, serves as KOL and Clinical Advisor to the company.

Forty51 Ventures is the seed investor of FERROSA and has been instrumental in the operational and financial set-up of the company. FERROSA was incorporated in Basel, Switzerland, a globally recognized hub for biotechnology and pharmaceutical innovation.

ABOUT FERROSA THERAPEUTICS

Ferrosa Therapeutics AG was founded in Basel, Switzerland by Forty51 Ventures in 2026. The company is developing a first-in-class bispecific antibody to treat anemia of inflammation across chronic kidney disease, autoimmune disease, and oncology. FERROSA’s dual-mechanism approach aims to restore iron homeostasis and effective erythropoiesis by addressing the cytokine-driven dysregulation at the heart of this condition. www.ferrosatx.com

ABOUT FORTY51 VENTURES

Forty51 Ventures is a venture capital firm with its core strategy focused on company formation in Biotech. Forty51 Ventures is a company builder leading first financing rounds of its growing portfolio of biotech companies www.forty51ventures.com

Contact:

Martin Stern
Chief Executive Officer
Ferrosa Therapeutics AG
[email protected] 
+41 79 818 06 32
www.ferrosatx.com

Logo: https://mma.prnewswire.com/media/2964149/Ferrosa_Therapeutics_Logo.jpg

SOURCE Ferrosa Therapeutics AG

Company partners with leading health plans, including Anthem and Health Net, to deliver a new model of care to millions of patients

KENMORE, Wash., April 23, 2026 — Zócalo Health, a tech-enabled, community-based primary care provider, today announced the close of $15 million in Series A funding, bringing the total raised to date to $22.75 million. The oversubscribed round was led by EO Ventures, with participation from Talipot and existing investors Vamos Ventures, Animo Ventures, Acumen America, Sorenson Ventures, BarronKent, and Kapor Center. The company will use the funds to accelerate nationwide expansion, scale its community-based workforce and deepen partnerships with health plans.

Funding comes as health plans face growing pressure to manage a small segment of members who drive a disproportionate share of healthcare costs. These patients, with complex medical, behavioral, and social needs, are historically difficult to engage in care. Zócalo Health is built specifically for this population, combining community-based care teams with virtual clinical services to drive sustained engagement, improve outcomes and reduce total cost of care within value-based frameworks.

“Zócalo Health has built a care model that performs in one of the most complex segments of healthcare,” said Roland Fryer, Founding Partner of EO Ventures and Harvard Professor of Economics. “It is demonstrating that community-based care, paired with the right operating model can scale and deliver meaningful results.”

Over the past year, Zócalo Health has demonstrated strong operating performance and early product-market fit. The company grew revenue approximately 4x year-over-year, expanded from two regional health plan partnerships in 2024 to more than a dozen in 2025, and is entering new markets across multiple states. The model has maintained high member retention, frequent monthly engagement and patient satisfaction scores that significantly exceed industry benchmarks.

A Model Built for Engagement and Retention

Zócalo Health is able to achieve outstanding outcomes for patients and health plans by organizing care around community health workers (CHWs), or promotoras de salud, who are embedded in the communities they serve. These teams are integrated with primary care providers, behavioral health clinicians, and care coordinators, enabling continuous engagement beyond traditional clinic settings. Notably, as patients have reported increased stress and anxiety, behavioral health has become a standout component of Zócalo Health’s model. Screening, care coordination and ongoing support are embedded into care delivery workflows, ensuring that behavioral health needs are addressed alongside medical and social needs from the start.

This integrated approach is designed specifically for members who are historically difficult to reach and retain. By focusing on proactive outreach, frequent touchpoints and trust-based relationships,  Zócalo Health successfully drives adherence and reduces avoidable utilization.

“We built Zócalo Health to consistently engage the patients the system misses,” said Erik Cardenas, Co-Founder and CEO. “Our model is designed around sustained engagement and outcomes. When you connect and engage RSS high-need members, you change both clinical outcomes and cost.”

Technology as a Scale Lever

As much as Zócalo Health has invested in developing personal relationships within communities, its sophisticated technology platform underlies operations for seamless care delivery. Its platform leverages AI to support and extend the capacity of frontline teams, allowing them to serve more members without sacrificing quality, while also improving how patients connect to care and community resources. The platform equips members with better visibility into their coverage and eligibility as well; it supports them alongside their CHWs in navigating Medicaid redetermination and evolving eligibility requirements.

Aligned with Health Plans, Built for Scale

Zócalo Health partners with Medicaid managed care organizations, including Anthem Blue Cross and Health Net, to deliver services aligned with broader state-led initiatives such as CalAIM across California. These programs are shaping a new blueprint for whole-person, community-based care that can be extended to other states over time.

The company’s growth has been driven by its ability to engage high-risk members, maintain strong retention, and operate with capital efficiency while expanding across geographies.

“Health plans are under pressure to deliver quality care for their most complex members, even as budgets tighten,” said Mariza Hardin, Co-Founder of Zócalo Health. “We’ve built a model that meets that challenge directly. This next phase is about scaling with discipline while maintaining both stellar performance and our deeply personal, community-driven touch.”

To learn more about Zócalo Health, the plans and segments it serves, and the services it offers, please visit www.zocalo.health.

About Zócalo Health

Zócalo Health is a community-based primary care provider delivering integrated medical, behavioral, and social care to underserved populations. The company partners with health plans to engage high-need members, improve outcomes, and reduce total cost of care through a model built on community health workers and technology-enabled care delivery.

SOURCE Zócalo Health

Die Finanzierungsrunde unter Führung von VP Capital und Oost NL beschleunigt die Einführung des Flaggschiffprodukts Repeltec und der patentierten wasserbasierten Löslichkeitstechnologie, während die EU ihre Pestizidvorschriften verschärft.

NIJMEGEN, Niederlande, 23. April 2026 — Affix Labs Group B.V., ein niederländisches Green-Chemtech-Startup, hat eine Finanzierungsrunde über 1 Million Euro unter Führung von VP Capital und Oost NL abgeschlossen. Das Unternehmen entwickelt ein wasserbasiertes Insektenschutzmittel, das die neurotoxischen Wirkstoffe ersetzt, die für die zunehmende Insektenresistenz verantwortlich sind. Mit dem neuen Kapital finanziert Affix Labs die europaweite Markteinführung.

Der Durchbruch: patentierte Löslichkeit und kontrollierte Freisetzung

Kern der Innovation ist eine Formulierungsmethode, mit der ölige, wasserunlösliche Wirkstoffe in wasserbasierten Systemen gelöst werden. Eine Schicht zur kontrollierten Freisetzung hält das Mittel bis zu zwölf Wochen wirksam. Das Flaggschiffprodukt Repeltec ist dermatologisch getestet und enthält keine neurotoxischen Verbindungen.

Sich verschärfende EU-Regulierung

Die EU verschärft ihre Vorschriften für chemische Pestizide. In Deutschland hat das Selbstbedienungsverbot 2025 eine breite Kategorie neurotoxischer Insektizide aus den offenen Regalen verdrängt, und andere Mitgliedstaaten ziehen mit ähnlichen Maßnahmen nach. Repeltec verfügt bereits über Wirkstoffzulassungen in Deutschland, Frankreich, Österreich und Norwegen.

Kommerzielle Expansion und B2B-Partnerschaften

Mit dem neuen Kapital baut Affix Labs seinen Vertrieb in Deutschland, Österreich, Frankreich und Norwegen aus. Großbritannien und Polen folgen. Neben den eigenen Verbraucherprodukten startet das Unternehmen ein White-Label-B2B-Modell unter dem Namen “Powered by Affix Labs”. FMCG-Unternehmen, Hotelleriebetriebe und Schädlingsbekämpfungshersteller können damit die Technologie in ihre eigenen Produktlinien integrieren.

Über Affix Labs

Affix Labs ist ein niederländisches Green-Chemtech-Startup, das die weltweite Abhängigkeit von Pestiziden verringert. Mit patentierter Löslichkeitstechnologie und Systemen zur kontrollierten Freisetzung schafft das Unternehmen langanhaltende, neurotoxinfreie Insektenbarrieren.

Pressekontakt

Tom Sam
[email protected]
www.affixlabs.com

Photo – https://mma.prnewswire.com/media/2964160/Affix_Labs.jpg
Logo – https://mma.prnewswire.com/media/2964159/Affix_Labs_Logo.jpg

Menée par VP Capital et Oost NL, cette levée de fonds accélère le déploiement du produit phare Repeltec et de la technologie brevetée de solubilité à base d’eau, dans un contexte de durcissement de la réglementation européenne sur les pesticides.

NIMÈGUE, Pays-Bas, 23 avril 2026 — Affix Labs Group B.V., une startup néerlandaise spécialisée dans la chimie verte (Green Chemtech), a bouclé une levée de fonds d’un million d’euros menée par VP Capital et Oost NL. L’entreprise développe un répulsif pour insectes à base d’eau qui remplace les substances actives neurotoxiques responsables de la résistance croissante des insectes. Le nouveau capital financera le déploiement européen.

La percée : solubilité brevetée et libération contrôlée

L’innovation centrale est une méthode de formulation qui permet de dissoudre dans l’eau des substances actives huileuses et insolubles. Une couche à libération contrôlée maintient l’efficacité du produit jusqu’à douze semaines. Le produit phare, Repeltec, est testé dermatologiquement et ne contient aucun composé neurotoxique.

Un cadre réglementaire européen qui se durcit

Les restrictions européennes sur les pesticides chimiques se durcissent. En Allemagne, l’interdiction du libre-service adoptée en 2025 a fait disparaître des rayons ouverts toute une catégorie d’insecticides neurotoxiques, et des mesures similaires sont en cours d’adoption dans d’autres États membres. Repeltec détient déjà des autorisations de substances actives en Allemagne, en France, en Autriche et en Norvège.

Expansion commerciale et partenariats B2B

Grâce au nouveau capital, Affix Labs étend sa distribution en Allemagne, en Autriche, en France et en Norvège. Le Royaume-Uni et la Pologne suivront. Parallèlement à ses gammes grand public, l’entreprise lance un modèle B2B en marque blanche sous le nom “Powered by Affix Labs”. Il permet aux entreprises FMCG, aux opérateurs hôteliers et aux fabricants de produits antiparasitaires d’intégrer la technologie dans leurs propres gammes.

À propos d’Affix Labs

Affix Labs est une startup néerlandaise Green Chemtech qui réduit la dépendance mondiale aux pesticides. Sa technologie de solubilité brevetée et ses systèmes à libération contrôlée créent des barrières anti-insectes durables et sans neurotoxiques.

Contact presse

Tom Sam
[email protected]
www.affixlabs.com

Photo – https://mma.prnewswire.com/media/2964160/Affix_Labs.jpg
Logo – https://mma.prnewswire.com/media/2964159/Affix_Labs_Logo.jpg

The funding round, led by VP Capital and Oost NL, accelerates the rollout of flagship product Repeltec and the company’s patented water-based solubility technology at a time when EU pesticide rules are tightening.

NIJMEGEN, Netherlands, April 23, 2026 — Affix Labs Group B.V., a Dutch Green Chemtech startup, has closed a €1 million funding round led by VP Capital and Oost NL. The company’s surface insect repellent replaces the neurotoxic active ingredients responsible for growing insect resistance with a water-based, controlled-release alternative. The new capital will fund the European rollout.

The Breakthrough: Patented Solubility and Controlled Release

The core innovation is a formulation method that dissolves oily, water-insoluble active ingredients into water-based systems. A controlled-release layer extends efficacy to 12 weeks. The flagship product, Repeltec, is dermatologically tested and contains no neurotoxic compounds.

A Tightening European Regulatory Environment

EU rules on chemical pesticides are tightening. Germany’s 2025 self-service ban pulled a broad category of neurotoxic insecticides from open retail shelves, and similar measures are now being adopted in other member states. Repeltec already holds active substance authorisations in Germany, France, Austria, and Norway.

Commercial Expansion and B2B Partnerships

With the new capital, Affix Labs is expanding distribution in Germany, Austria, France, and Norway, with the UK and Poland to follow. Alongside its consumer product lines, the company is launching a white-label B2B model under the name “Powered by Affix Labs”. FMCG companies, hospitality operators, and pest control manufacturers can use it to integrate the technology into their own product ranges.

About Affix Labs

Affix Labs is a Dutch Green Chemtech startup working to reduce global pesticide dependency. Its patented solubility technology and controlled-release systems create long-lasting, neurotoxic-free insect barriers.

Media Contact

Tom Sam
[email protected]
www.affixlabs.com

Photo – https://mma.prnewswire.com/media/2964160/Affix_Labs.jpg
Logo – https://mma.prnewswire.com/media/2964159/Affix_Labs_Logo.jpg

SHENZHEN, China, April 23, 2026 — Pudu Robotics, a global leader in commercial service robotics, today announced that it has raised nearly USD 150 million in a new funding round. Following this round, the company’s valuation has exceeded USD 1.5 billion, reflecting the capital market’s strong confidence in Pudu’s technical barriers, commercial scalability, and global leadership. With this latest round, Pudu’s cumulative funding now exceeds USD 300 million.

Proceeds from the financing will be strategically deployed to accelerate the development of embodied AI technologies, expand the company’s product portfolio, deepen global market expansion, scale manufacturing capacity, and further strengthen supply chain capabilities. These initiatives are designed to reinforce the company’s leadership in the rapidly evolving commercial service robotics sector and laying a solid foundation for future capital market milestones.

Pudu Robotics has emerged as one of the fastest-growing companies in the commercial service robotics sector, with a diversified portfolio spanning service delivery, commercial cleaning, industrial delivery and general embodied AI robotics. This multi-sector approach resulted in a remarkable 100% year-over-year revenue surge in 2025. Notably, the company’s commercial cleaning segment has grown to represent over 70% of total revenue, while its industrial delivery robots have seen rapid adoption with over 4,000 units shipped within just one year of their market launch.

This commercial success is further validated by Pudu’s extensive global footprint, with its solutions widely adopted by leading global brands including Carrefour, Walmart, and EDEKA. According to Frost & Sullivan’s “Market Research on Global Commercial Service Robotics (2023)”, Pudu Robotics commands a 23% global market share, ranking first worldwide and maintaining the industry’s leading position in international deployments.

Headquartered in Shenzhen with dedicated R&D centers in Chengdu and Hong Kong, the company continues to push technical boundaries through the full-stack development of core components, including navigation algorithms, multi-robot scheduling, motion controllers, and integrated joint modules.

Felix Zhang, Founder and CEO of Pudu Robotics, said: “This funding milestone is a powerful validation of Pudu’s industry leadership, product and technological strength, global brand, and commercial infrastructure. Backed by our strategic investors and industrial partners, Pudu will continue to push the boundaries of embodied AI and commercial service robotics. We remain committed to innovating with the spirit of an inventor and leveraging a global vision to accelerate robot adoption, elevating the industry to new heights in the global value chain.”

About Pudu Robotics

Pudu Robotics, a global leader in the commercial service robotics sector, is dedicated to empowering easier work and better lives through AI and robotics, with a vision of building a global intelligent robotics infrastructure that serves 10 billion people worldwide.

Built on three core technologies—mobility, manipulation, and interaction—Pudu Robotics has pioneered an “One Brain, Multiple Embodiments” architecture, establishing a comprehensive product portfolio that includes specialized, semi-humanoid, and humanoid robots.

Currently, Pudu offers four major product lines: service delivery, commercial cleaning, industrial delivery and general embodied AI. Its solutions are widely deployed across industries such as retail, hospitality, manufacturing and industrial facilities, food and beverage, real estate and property services, healthcare, entertainment and sport, education, and public services.

To date, Pudu Robotics has shipped over 120,000 units globally, with a presence in more than 80 countries and regions.

Photo – https://mma.prnewswire.com/media/2963940/Pudu_Robotics_Raises_Nearly_USD_150_Million_Exceeds_USD_1.jpg
Logo – https://mma.prnewswire.com/media/2492578/5933534/Pudu_Robotics_Logo.jpg

DALLAS, April 22, 2026 — IGCS International, a CVE-certified SDVOSB and leading provider of mission support and MRO supplies to the U.S. Department of Defense and federal agencies, today announced that Lacks Enterprises has acquired an equity stake in the company.

The strategic investment combines IGCS’s expertise in government supply chain, logistics, and MRO solutions with Lacks Enterprises’ advanced manufacturing capabilities, including electroplating, injection molding, composites, and testing for aerospace and defense.

“IGCS has built a strong track record supporting the Department of Defense… Partnering with Lacks Enterprises allows us to integrate cutting-edge manufacturing innovation into our offerings,” said Russ Spears, President of IGCS International.

Media Contact: Russ Spears, 214-733-7278, [email protected]

SOURCE IGCS International

Partnership with LA4LA will accelerate construction of affordable and mixed-use housing across LA County

SACRAMENTO, Calif., April 22, 2026 — Health Net, one of California’s most experienced Medi-Cal managed care health plans and a Centene Corporation (NYSE: CNC) company, announced a $10 million investment in LA4LA’s “Guarantee Fund,” which will support the expedited construction of affordable and mixed-income housing across Los Angeles County.

The “Guarantee Fund” offers subsidies to help housing developers secure financing quickly for affordable rental projects, reducing start-up times and making new housing available faster for communities in need.

“Safe, stable housing is one of the most powerful prescriptions for better health — we’ve seen it change lives,” said Dorothy Seleski, Medi-Cal President at Health Net. “This investment won’t just finance projects — it will unlock homes, restore hope and give thousands of Angelenos healthier tomorrows. That means a sense of stability — stronger connections to care, fewer trips to the emergency room and a little more breathing room each day for people to work, learn and heal.”

In Los Angeles County, there are:

Health Net’s investment is designed to help address these gaps by supporting housing developments that include a mix of low-income, voucher-supported, and middle-income units, with up to 30% reserved for voucher holders.

“This investment will help continue the progress we’ve made accelerating the production of affordable housing and decreasing homelessness across Los Angeles,” said Mayor Karen Bass. “I want to thank the LA4LA and Health Net teams for their continued partnership and for supporting innovative solutions to bridge gaps and build more affordable, stable housing citywide.”

When lenders are confident that subsidy payments like Section 8 or VASH vouchers will be made reliably, they can provide larger loans and finance more projects. LA4LA helps lenders provide larger loans and move more housing projects forward, particularly in neighborhoods near jobs, parks and schools and where residents will also have access to community resources. This closes financing gaps that can stall approved developments and encourages broader participation from property owners.

“We’re grateful to Health Net for their commitment to innovative housing solutions,” said Sarah Dusseault, Lead Strategist for LA4LA. “Their investment in the Guarantee Tool will transform how projects approach financing and increase the viability of affordable housing. As developments are completed and no longer require guarantees, Health Net’s capital can be redeployed — creating a sustainable cycle that supports additional projects over time.”

Health Net’s investment can be deployed across multiple sites countywide and, when combined with public subsidies and private lending, helps unlock significantly more housing development in the region.

This investment builds on Health Net’s broader commitment to addressing housing and homelessness across California. Since 2020, Health Net has dedicated a total of $93 million in investments related to housing and supportive services for unhoused individuals.

About Health Net
Founded in California more than 45 years ago, Health Net, LLC (“Health Net”), a company of Centene Corporation, believes that every person deserves a safety net for their health, regardless of age, income, employment status or current state of health. Today, we provide health plans for individuals, families, businesses of every size and people who qualify for Medi-Cal or Medicare. With more than 117,000 of our network providers, Health Net serves more than three million members across the state. We also offer access to substance abuse programs, behavioral health services and managed healthcare products related to prescription drugs. We make these health plans and services available through Health Net and its subsidiaries: Health Net of California, Inc., Health Net Life Insurance Company and Health Net Community Solutions, Inc. These entities are wholly owned subsidiaries of Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to transforming the health of the communities we serve, one person at a time. Health Net and Centene Corporation employ more than 5,700 people in California who work at one of five regional Talent Hub offices. For more information, visit www.HealthNet.com.
http://www.healthnet.com/

About LA4LA
LA4LA is a public-private partnership housed with the California Community Foundation and supported with initial funding from the Conrad N Hilton Foundation. Our donors and supporters include philanthropy, financial institutions, and individuals and companies who care about the future of Los Angeles. At LA4LA, they bring together experts on housing, development and financing to tackle some of the most common barriers stalling affordable housing construction today: the scarcity of financing and the high cost and volatility of interest. To learn more or get involved, visit www.la4la.org or contact [email protected].

SOURCE Health Net, LLC